



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2010	2009	% Change			2010	2009	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>CONSUMER SEGMENT <sup>(2)</sup></b>										
<b>SKIN CARE</b>										
US	311	370	-15.9%	-15.9%	-	1,185	1,204	-1.6%	-1.6%	-
Intl	489	472	3.6%	3.7%	-0.1%	1,378	1,313	5.0%	2.0%	3.0%
WW	800	842	-5.0%	-4.9%	-0.1%	2,563	2,517	1.8%	0.2%	1.6%
<b>BABY CARE</b>										
US	104	102	2.0%	2.0%	-	306	308	-0.6%	-0.6%	-
Intl	462	442	4.5%	3.6%	0.9%	1,326	1,233	7.5%	3.3%	4.2%
WW	566	544	4.0%	3.3%	0.7%	1,632	1,541	5.9%	2.5%	3.4%
<b>ORAL CARE</b>										
US	164	187	-12.3%	-12.3%	-	486	549	-11.5%	-11.5%	-
Intl	220	223	-1.3%	-2.2%	0.9%	651	612	6.4%	1.3%	5.1%
WW	384	410	-6.3%	-6.8%	0.5%	1,137	1,161	-2.1%	-4.8%	2.7%
<b>OTC/NUTRITIONALS</b>										
US	438	732	-40.2%	-40.2%	-	1,472	2,137	-31.1%	-31.1%	-
Intl	671	666	0.8%	3.5%	-2.7%	1,985	1,919	3.4%	0.7%	2.7%
WW	1,109	1,398	-20.7%	-19.4%	-1.3%	3,457	4,056	-14.8%	-16.1%	1.3%
<b>WOMEN'S HEALTH</b>										
US	121	142	-14.8%	-14.8%	-	404	443	-8.8%	-8.8%	-
Intl	338	360	-6.1%	-5.1%	-1.0%	990	963	2.8%	-0.4%	3.2%
WW	459	502	-8.6%	-7.9%	-0.7%	1,394	1,406	-0.9%	-3.1%	2.2%
<b>WOUND CARE/OTHER</b>										
US	139	158	-12.0%	-12.0%	-	447	484	-7.6%	-7.6%	-
Intl	110	135	-18.5%	-18.5%	0.0%	350	389	-10.0%	-13.9%	3.9%
WW	249	293	-15.0%	-15.0%	0.0%	797	873	-8.7%	-10.4%	1.7%
<b>TOTAL CONSUMER</b>										
US	1,277	1,691	-24.5%	-24.5%	-	4,300	5,125	-16.1%	-16.1%	-
Intl	2,290	2,298	-0.3%	0.4%	-0.7%	6,680	6,429	3.9%	0.5%	3.4%
WW	3,567	3,989	-10.6%	-10.2%	-0.4%	10,980	11,554	-5.0%	-6.9%	1.9%

See footnotes on last page

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	THIRD QUARTER					NINE MONTHS				
	2010	2009	% Change			2010	2009	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT <sup>(2) (6)</sup></b>										
<u>ACIPHEX/PARIET</u>										
US	116	131	-11.5%	-11.5%	-	356	397	-10.3%	-10.3%	-
Intl	124	130	-4.6%	0.8%	-5.4%	398	387	2.8%	2.0%	0.8%
WW	240	261	-8.0%	-5.3%	-2.7%	754	784	-3.8%	-4.2%	0.4%
<u>CONCERTA</u>										
US	214	205	4.4%	4.4%	-	668	707	-5.5%	-5.5%	-
Intl	85	79	7.6%	9.3%	-1.7%	283	238	18.9%	14.3%	4.6%
WW	299	284	5.3%	5.8%	-0.5%	951	945	0.6%	-0.6%	1.2%
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>										
US	42	38	10.5%	10.5%	-	117	163	-28.2%	-28.2%	-
Intl	142	168	-15.5%	-14.2%	-1.3%	435	492	-11.6%	-13.4%	1.8%
WW	184	206	-10.7%	-9.6%	-1.1%	552	655	-15.7%	-17.1%	1.4%
<u>LEVAQUIN/FLOXIN</u>										
US	274	294	-6.8%	-6.8%	-	926	1,045	-11.4%	-11.4%	-
Intl	12	17	-29.4%	-31.5%	2.1%	31	53	-41.5%	-44.2%	2.7%
WW	286	311	-8.0%	-8.1%	0.1%	957	1,098	-12.8%	-12.9%	0.1%
<u>PREZISTA</u>										
US	102	78	30.8%	30.8%	-	290	215	34.9%	34.9%	-
Intl	128	73	75.3%	82.7%	-7.4%	331	198	67.2%	66.8%	0.4%
WW	230	151	52.3%	55.9%	-3.6%	621	413	50.4%	50.2%	0.2%
<u>PROCRIT/EPREX</u>										
US	204	299	-31.8%	-31.8%	-	800	950	-15.8%	-15.8%	-
Intl	202	243	-16.9%	-11.9%	-5.0%	655	719	-8.9%	-9.2%	0.3%
WW	406	542	-25.1%	-22.9%	-2.2%	1,455	1,669	-12.8%	-12.9%	0.1%
<u>REMICADE</u>										
US	857	822	4.3%	4.3%	-	2,420	2,330	3.9%	3.9%	-
US Exports <sup>(3)</sup>	365	208	75.5%	75.5%	-	1,106	821	34.7%	34.7%	-
Intl	7	6	16.7%	16.7%	-	19	15	26.7%	26.7%	0.0%
WW	1,229	1,036	18.6%	18.6%	-	3,545	3,166	12.0%	12.0%	-
<u>RISPERDAL/RISPERIDONE</u>										
US	(2)	35	-105.7%	-105.7%	-	(14)	223	-106.3%	-106.3%	-
Intl	123	157	-21.7%	-22.8%	1.1%	390	483	-19.3%	-21.7%	2.4%
WW	121	192	-37.0%	-37.9%	0.9%	376	706	-46.7%	-48.4%	1.7%
<u>RISPERDAL CONSTA</u>										
US	108	129	-16.3%	-16.3%	-	340	386	-11.9%	-11.9%	-
Intl	270	224	20.5%	26.6%	-6.1%	772	640	20.6%	20.3%	0.3%
WW	378	353	7.1%	11.0%	-3.9%	1,112	1,026	8.4%	8.2%	0.2%
<u>TOPAMAX</u>										
US	46	72	-36.1%	-36.1%	-	162	642	-74.8%	-74.8%	-
Intl	81	103	-21.4%	-18.1%	-3.3%	255	317	-19.6%	-20.5%	0.9%
WW	127	175	-27.4%	-25.4%	-2.0%	417	959	-56.5%	-56.8%	0.3%
<u>VELCADE</u>										
US	-	-	-	-	-	-	-	0.0%	0.0%	-
Intl	246	231	6.5%	10.1%	-3.6%	793	652	21.6%	20.3%	1.3%
WW	246	231	6.5%	10.1%	-3.6%	793	652	21.6%	20.3%	1.3%
<u>OTHER</u>										
US	728	546	33.3%	33.3%	-	2,199	1,824	20.6%	20.6%	-
Intl	1,021	961	6.2%	7.4%	-1.2%	2,954	2,630	12.3%	9.4%	2.9%
WW	1,749	1,507	16.1%	16.9%	-0.8%	5,153	4,454	15.7%	14.0%	1.7%
<b>TOTAL PHARMACEUTICAL</b>										
US	3,054	2,857	6.9%	6.9%	-	9,370	9,703	-3.4%	-3.4%	-
Intl	2,441	2,392	2.0%	4.6%	-2.6%	7,316	6,824	7.2%	5.3%	1.9%
WW	5,495	5,249	4.7%	5.9%	-1.2%	16,686	16,527	1.0%	0.2%	0.8%
<b>MAJOR NEW PHARM PRODUCTS <sup>(4)</sup></b>										
<u>INVEGA</u>										
US	63	61	3.3%	3.3%	-	200	194	3.1%	3.1%	-
Intl	35	36	-2.8%	1.7%	-4.5%	108	93	16.1%	15.2%	0.9%
WW	98	97	1.0%	2.7%	-1.7%	308	287	7.3%	7.0%	0.3%

See footnotes on last page

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

	THIRD QUARTER					NINE MONTHS				
	2010	2009	% Change			2010	2009	% Change		
			Reported	Operational <sup>(1)</sup>	Currency			Reported	Operational <sup>(1)</sup>	Currency
<b>MEDICAL DEVICES AND DIAGNOSTICS <sup>(2)</sup></b>										
<u>CORDIS <sup>(5)</sup></u>										
US	246	233	5.6%	5.6%	-	762	731	4.2%	4.2%	-
Intl	350	407	-14.0%	-13.5%	-0.5%	1,161	1,251	-7.2%	-9.4%	2.2%
WW	596	640	-6.9%	-6.6%	-0.3%	1,923	1,982	-3.0%	-4.4%	1.4%
<u>DEPUY</u>										
US	748	740	1.1%	1.1%	-	2,338	2,268	3.1%	3.1%	-
Intl	561	544	3.1%	4.8%	-1.7%	1,800	1,631	10.4%	7.3%	3.1%
WW	1,309	1,284	1.9%	2.6%	-0.7%	4,138	3,899	6.1%	4.8%	1.3%
<u>DIABETES CARE</u>										
US	338	332	1.8%	1.8%	-	941	908	3.6%	3.6%	-
Intl	275	302	-8.9%	0.2%	-9.1%	885	877	0.9%	2.1%	-1.2%
WW	613	634	-3.3%	1.0%	-4.3%	1,826	1,785	2.3%	2.9%	-0.6%
<u>ETHICON</u>										
US	480	439	9.3%	9.3%	-	1,499	1,296	15.7%	15.7%	-
Intl	592	580	2.1%	3.4%	-1.3%	1,852	1,717	7.9%	5.3%	2.6%
WW	1,072	1,019	5.2%	6.0%	-0.8%	3,351	3,013	11.2%	9.7%	1.5%
<u>ETHICON ENDO-SURGERY</u>										
US	484	499	-3.0%	-3.0%	-	1,474	1,442	2.2%	2.2%	-
Intl	653	607	7.6%	8.4%	-0.8%	2,027	1,794	13.0%	9.9%	3.1%
WW	1,137	1,106	2.8%	3.3%	-0.5%	3,501	3,236	8.2%	6.5%	1.7%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>										
US	263	285	-7.7%	-7.7%	-	815	846	-3.7%	-3.7%	-
Intl	235	216	8.8%	9.2%	-0.4%	702	616	14.0%	11.1%	2.9%
WW	498	501	-0.6%	-0.4%	-0.2%	1,517	1,462	3.8%	2.6%	1.2%
<u>VISION CARE</u>										
US	241	238	1.3%	1.3%	-	722	703	2.7%	2.7%	-
Intl	454	421	7.8%	4.0%	3.8%	1,299	1,185	9.6%	4.9%	4.7%
WW	695	659	5.5%	3.1%	2.4%	2,021	1,888	7.0%	4.0%	3.0%
<b>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</b>										
US	2,800	2,766	1.2%	1.2%	-	8,551	8,194	4.4%	4.4%	-
Intl	3,120	3,077	1.4%	2.6%	-1.2%	9,726	9,071	7.2%	4.5%	2.7%
WW	5,920	5,843	1.3%	1.9%	-0.6%	18,277	17,265	5.9%	4.5%	1.4%

<sup>(1)</sup> Operational growth excludes the effect of currency

<sup>(2)</sup> Select areas (unaudited)

<sup>(3)</sup> Reported in U.S. sales

<sup>(4)</sup> Included in Other

<sup>(5)</sup> Includes sales of Drug-Eluting Stents for Q3 2010 of \$47, \$89 and \$136MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q3 2009 of \$53, \$158 and \$211MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for September YTD 2010 of \$166, \$327 and \$493MM Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for September YTD 2009 of \$189, \$507 and \$696MM Domestic, International and Worldwide respectively

<sup>(6)</sup> Conforms to current presentation